Medicamen Biotech

MEDICAMEQ · NSE

— · —

₹346.3

Closing price — 17 Sept 2026

Market cap ₹405 Cr · EPS ₹10.28

Valuation

Blended fair value using DCF and peer comparison methods.

See if Medicamen Biotech is undervalued

Unlock intrinsic value for 4,800+ Indian stocks — free.

FCF adjusted for working capital timing. Based on earnings conversion.

The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.

Peer comparison

How this company stacks up against sector peers on valuation and quality metrics.

Branded generics & specialty pharma · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
Medicamen Biotech MEDICAMEQ · you	₹372 Cr	40.4×	1.4×	19.7×	3.5%	4.9%	12.0%
Sector median	—	21.1×	2.4×	11.6×	10.4%	0.1%	3.4%
Hikal Limited HIKAL	₹2,625 Cr	—	2.3×	—	-4.1%	-2.8%	-5.4%
Venus Remedies Limited VENUSREM	₹2,388 Cr	21.1×	4.8×	—	22.9%	0.1%	—
Indoco Remedies Limited INDOCO	₹2,040 Cr	—	2.2×	—	-10.1%	-5.2%	3.4%
Windlas Biotech Limited WINDLAS	₹2,010 Cr	29.5×	4.2×	—	14.1%	0.1%	—
Solara Active Pharma Sciences Limited SOLARA	₹1,746 Cr	—	2.2×	9.9×	-0.6%	-0.5%	-1.8%
Fermenta Biotech Limited FERMENTA	₹1,325 Cr	14.5×	2.5×	11.6×	17.7%	13.7%	14.5%
Lincoln Pharmaceuticals Limited LINCOLN	₹1,272 Cr	14.3×	1.7×	13.1×	11.6%	13.1%	9.6%
Themis Medicare Limited THEMISMED	₹964 Cr	32.2×	3.0×	—	9.2%	0.3%	—

Peer comparison verdict

Medicamen trades at a premium to sector peers on P/E (43.9× vs median 21.1×). The market is pricing in higher growth — worth verifying whether recent revenue trends support that expectation.

Business quality

Valuation

P/E ratio

43.9×

P/B ratio

—

EV/EBITDA

—

Price/Sales

—

Returns

ROE

3.5%

ROCE

4.4%

ROA

—

Growth

Revenue CAGR (3yr)

12.0%

EPS CAGR (3yr)

-13.4%

Efficiency

Asset turnover

—

FCF yield

-9.4%

Dividend yield

0.3%

Liquidity & Solvency

Debt / Equity

0.15×

Debt / EBITDA

—

Interest coverage

3.5×

Current ratio

2.54×

Quick ratio

—

Financial health

Piotroski F-Score, Altman Z-Score, and key solvency ratios.

Financial health data is not yet available for this company.

Full financial data

Charts and annual statements for income, balance sheet and cash flow.

Income trend

Revenue, profit and margin trends over time.

Revenue

Net profit

Operating margin

Net margin

Revenue

₹198 Cr

Net profit

₹10 Cr

Operating margin

—

Net margin

4.9%

Revenue and net profit in ₹ Crores (left axis). Margins % on right axis.

Cash flow

Where cash comes from and where it goes.

Operating CFInvesting CFFinancing CFFree cash flow

Operating CF — Cash earned from running the business. The core engine of financial health.

Investing CF — Cash spent on assets and equipment. Negative is normal — it means the company is investing in growth.

Financing CF — Cash from borrowing or repaying loans and dividends. Negative means debt is being repaid.

Free cash flow — Operating CF minus capex. Cash left after keeping the business running. Positive and growing is ideal.

Operating CF

-₹33.17 Cr

Investing CF

₹0 Cr

Financing CF

₹0 Cr

Free cash flow

-₹37.95 Cr

Balance sheet

Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.

How the company is funded — equity is owners' money, debt is long-term borrowing, current liabilities are short-term obligations.

Equity

Debt

Current liabilities

Total assets

—

Total debt

₹42 Cr

Equity

₹276 Cr

Debt / Equity

0.15×

Numbers are illustrative — order-of-magnitude correct. For precise figures, refer to the company's annual report on BSE/NSE.

Shareholding pattern

Who owns this company and how that has changed.

What shareholding tells you: When promoters (founders/controlling shareholders) increase their stake, it usually signals confidence in the business. Rising FII (foreign funds) interest means international money is moving in. High promoter pledge is a risk — pledged shares can be force-sold if the stock price falls sharply.

Latest quarter

Promoter

40.5%

FII

0.1%

-0.0 pp QoQ

DII

0.5%

+0.4 pp QoQ

Retail

59.0%

Trend over time (%)

Quarterly data

Category	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Change (YoY)
Promoter	43.2%	43.2%	43.2%	43.0%	43.0%	43.0%	43.2%	40.5%	40.5%	40.5%	40.5%	40.5%	0.0 ppYoY
FII (Foreign)	0.2%	0.2%	0.1%	0.1%	0.1%	0.1%	0.1%	0.0%	0.1%	0.0%	0.1%	0.1%	+0.1 ppYoY
DII (Domestic)	0.2%	0.7%	1.0%	1.2%	1.2%	0.9%	0.8%	0.7%	0.6%	0.5%	0.1%	0.5%	-0.2 ppYoY
Retail	56.4%	55.9%	55.7%	55.8%	55.8%	56.0%	56.0%	58.8%	58.8%	59.0%	59.4%	59.0%	+0.2 ppYoY

Signals from the trend

📉

PromoterDown 2.8pp — worth monitoring for further declines

➡️

FIIStable

➡️

DIIStable

Overall cautious — promoter selling warrant monitoring.

pp = percentage points. FII = Foreign Institutional Investors. DII = Domestic Institutional Investors (MFs, insurance). Data sourced from NSE/BSE filings. Verify on BSE/NSE before any investment decision.